血清肿瘤标志物水平评价晚期非小细胞肺癌靶向治疗价值研究
|
摘要
目的探究血清肿瘤标志物水平评价晚期非小细胞肺癌靶向治疗价值。方法选自本院2016年3月~2017年3月经晚期非小细胞肺癌靶向治疗的80例患者,所有患者均实施靶向治疗,观察患者治疗前及治疗后各项血清肿瘤标志物水平情况。结果 80例患者治疗有效例数为39例(48.75%),无效为41例(51.25%)。按照治疗效果分为有效组与无效组。两组治疗前各项血清肿瘤标志物水平比较差异无统计学意义(P>0.05);治疗后,有效组各项血清肿瘤标志物水平优于无效组(P<0.05)。不同病理类型晚期NSCLC肿瘤标志物血清水平比较差异有统计学意义(P<0.05);而CEA、CA125水平依次从腺癌、腺鳞癌及鳞癌减低,SCC、CYFAR21-1依次从腺癌、腺鳞癌及鳞癌升高。单项肿瘤标志物检测的敏感度、特异度与准确度中,CA125敏感度及准确度最高、特异度最低,而CEA特异度最高。结论血清肿瘤标志物水平可有效评价晚期非小细胞肺癌靶向治疗的临床疗效。
Objective To explore the value of serum tumor markers level in the evaluation of targeted therapy for advanced non-small cell lung cancer. Methods Eighty patients with advanced non-small cell lung cancer who underwent targeted treatment in our hospital from March 2016 to March 2017 were selected.All patients were treated with targeted therapy.The levels of serum tumor markers before and after treatment were observed. Results The effective number of 80 cases was 39 cases(48.75%),and 41 cases were invalid(51.25%).According to the therapeutic effect,they were divided into effective group and ineffective group.There was no significant difference in serum tumor markers between the two groups before treatment(P > 0.05).After treatment,the serum tumor markers in the effective group were better than those in the ineffective group(P < 0.05).There was significant difference in serum levels of advanced NSCLC tumor markers in different pathological types(P < 0.05),while CEA and CA125 levels decreased in turn from adenocarcinoma,adenosscale and squamous cell carcinoma,and SCC and CYFAR21-1 were increased from adenocarcinoma,adenosscale and squamous cell carcinoma in turn.Among the sensitivity,specificity and accuracy of single tumor markers,the sensitivity and accuracy of CA125 were the highest and the specificity was the lowest,while CEA specificity was the highest. Conclusion The level of serum tumor markers can effectively evaluate the clinical efficacy of targeted therapy for advanced non-small cell lung cancer.
Objective To explore the value of serum tumor markers level in the evaluation of targeted therapy for advanced non-small cell lung cancer. Methods Eighty patients with advanced non-small cell lung cancer who underwent targeted treatment in our hospital from March 2016 to March 2017 were selected.All patients were treated with targeted therapy.The levels of serum tumor markers before and after treatment were observed. Results The effective number of 80 cases was 39 cases(48.75%),and 41 cases were invalid(51.25%).According to the therapeutic effect,they were divided into effective group and ineffective group.There was no significant difference in serum tumor markers between the two groups before treatment(P > 0.05).After treatment,the serum tumor markers in the effective group were better than those in the ineffective group(P < 0.05).There was significant difference in serum levels of advanced NSCLC tumor markers in different pathological types(P < 0.05),while CEA and CA125 levels decreased in turn from adenocarcinoma,adenosscale and squamous cell carcinoma,and SCC and CYFAR21-1 were increased from adenocarcinoma,adenosscale and squamous cell carcinoma in turn.Among the sensitivity,specificity and accuracy of single tumor markers,the sensitivity and accuracy of CA125 were the highest and the specificity was the lowest,while CEA specificity was the highest. Conclusion The level of serum tumor markers can effectively evaluate the clinical efficacy of targeted therapy for advanced non-small cell lung cancer.
引文
[1]刘芳.血清肿瘤标志物联合检测在非小细胞肺癌脑转移诊疗中的价值[J].实用癌症杂志,2017,32(4):578-581.
[2]沈娟,周芸,夏守慧,等.血清肿瘤标志物联合检测在非小细胞肺癌诊断中的价值[J].中国实用医药,2017,12(5):1-3.
[3]季禹乔,孙明忠,朱晖,等.血清mi RNA-21与肿瘤标志物CEA、CYFRA21-1、NSE对早期非小细胞肺癌的诊断价值[J].中国实验诊断学,2017,21(4):576-581.
[4]宋晓,蔡振旭,杜炜,等.血清肿瘤标志物在非小细胞肺癌放化疗后疗效评估和预后判断中的价值[J].中国医药,2016,11(5):664-666.
[5]王丹.血清中CEA、CA125、Cyfra21-1联合SCCAg在评价晚期非小细胞肺癌靶向治疗的临床意义[J].航空航天医学杂志,2017,28(4):429-431.
[6]张艳,刘晶,杨梦迪.非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义[J].临床药物治疗杂志,2014,12(5):35-39.
[7]季德成.血清肿瘤标志物水平评价晚期非小细胞肺癌靶向治疗效果的价值[J].中国医药,2016,11(2):199-202.
[8]陆英杰,张辉标,张学林,等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者疗效及血清肿瘤标志物的影响[J].现代生物医学进展,2017,17(8):1562-1565.
[9]田伟,豆亚伟,戴云,等.不同化疗方案治疗晚期非小细胞肺癌的临床疗效及肿瘤标志物与疗效的相关性研究[J].河北医学,2016,22(8):1305-1307.
[10]牛艳柳,邹明瑾,阿尔孜古丽,等.晚期非小细胞肺癌患者EGFR基因突变及其与血清肿瘤标志物的相关性[J].检验医学与临床,2017,14(17):2583-2586.
[11]李媛.晚期非小细胞肺癌患者放疗前后肿瘤标志物变化与近期疗效的临床分析[J].中国实验诊断学,2017,21(8):1335-1337.
[12]张天,苑惠敏,毛凯,等.晚期非小细胞肺癌患者放疗前后肿瘤标志物变化与近期疗效的临床分析[J].中华放射医学与防护杂志,2013,33(3):290-293.
[13]陈淑云,顾文刚,于莉.联合检测血清肿瘤标志物对非小细胞肺癌的诊断价值[J].武警医学,2013,24(10):887-888.
[14]田应选,余敏,孙莉,等.五种血清肿瘤标志物检测对非小细胞肺癌术后复发诊断研究[J].现代检验医学杂志,2014,29(3):37-39.
[15]殷金兰,李莹,陈金梅,等.4项肿瘤标志物检测在晚期非小细胞肺癌治疗中的意义[J].国际检验医学杂志,2017,38(14):1985-1987.
[2]沈娟,周芸,夏守慧,等.血清肿瘤标志物联合检测在非小细胞肺癌诊断中的价值[J].中国实用医药,2017,12(5):1-3.
[3]季禹乔,孙明忠,朱晖,等.血清mi RNA-21与肿瘤标志物CEA、CYFRA21-1、NSE对早期非小细胞肺癌的诊断价值[J].中国实验诊断学,2017,21(4):576-581.
[4]宋晓,蔡振旭,杜炜,等.血清肿瘤标志物在非小细胞肺癌放化疗后疗效评估和预后判断中的价值[J].中国医药,2016,11(5):664-666.
[5]王丹.血清中CEA、CA125、Cyfra21-1联合SCCAg在评价晚期非小细胞肺癌靶向治疗的临床意义[J].航空航天医学杂志,2017,28(4):429-431.
[6]张艳,刘晶,杨梦迪.非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义[J].临床药物治疗杂志,2014,12(5):35-39.
[7]季德成.血清肿瘤标志物水平评价晚期非小细胞肺癌靶向治疗效果的价值[J].中国医药,2016,11(2):199-202.
[8]陆英杰,张辉标,张学林,等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者疗效及血清肿瘤标志物的影响[J].现代生物医学进展,2017,17(8):1562-1565.
[9]田伟,豆亚伟,戴云,等.不同化疗方案治疗晚期非小细胞肺癌的临床疗效及肿瘤标志物与疗效的相关性研究[J].河北医学,2016,22(8):1305-1307.
[10]牛艳柳,邹明瑾,阿尔孜古丽,等.晚期非小细胞肺癌患者EGFR基因突变及其与血清肿瘤标志物的相关性[J].检验医学与临床,2017,14(17):2583-2586.
[11]李媛.晚期非小细胞肺癌患者放疗前后肿瘤标志物变化与近期疗效的临床分析[J].中国实验诊断学,2017,21(8):1335-1337.
[12]张天,苑惠敏,毛凯,等.晚期非小细胞肺癌患者放疗前后肿瘤标志物变化与近期疗效的临床分析[J].中华放射医学与防护杂志,2013,33(3):290-293.
[13]陈淑云,顾文刚,于莉.联合检测血清肿瘤标志物对非小细胞肺癌的诊断价值[J].武警医学,2013,24(10):887-888.
[14]田应选,余敏,孙莉,等.五种血清肿瘤标志物检测对非小细胞肺癌术后复发诊断研究[J].现代检验医学杂志,2014,29(3):37-39.
[15]殷金兰,李莹,陈金梅,等.4项肿瘤标志物检测在晚期非小细胞肺癌治疗中的意义[J].国际检验医学杂志,2017,38(14):1985-1987.